The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?

Francesco Pantano, Matteo Santoni, Giuseppe Procopio, Mimma Rizzo, Roberto Iacovelli, Camillo Porta, Alessandro Conti, Antonio Lugini, Michele Milella, Luca Galli, Cinzia Ortega, Francesco Maria Guida, Marianna Silletta, Giovanni Schinzari, Elena Verzoni, Daniela Modica, Pierfilippo Crucitti, Annamaria Rauco, Alessandra Felici, Valentina BallatoreStefano Cascinu, Giuseppe Tonini, Giacomo Carteni, Antonio Russo, Daniele Santini

Research output: Contribution to journalArticle

Abstract

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC.

Original languageEnglish
Article numbere0120427
JournalPLoS One
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 17 2015

Fingerprint

Pharmacodynamics
pharmacology
kidney cells
Lipid Metabolism
Renal Cell Carcinoma
lipid metabolism
carcinoma
Cells
body mass index
Body Mass Index
Blood pressure
Sirolimus
multivariate analysis
Blood Glucose
Triglycerides
Multivariate Analysis
Cholesterol
Basal Bodies
Survival
normal values

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus : A new pharmacodynamic marker? / Pantano, Francesco; Santoni, Matteo; Procopio, Giuseppe; Rizzo, Mimma; Iacovelli, Roberto; Porta, Camillo; Conti, Alessandro; Lugini, Antonio; Milella, Michele; Galli, Luca; Ortega, Cinzia; Guida, Francesco Maria; Silletta, Marianna; Schinzari, Giovanni; Verzoni, Elena; Modica, Daniela; Crucitti, Pierfilippo; Rauco, Annamaria; Felici, Alessandra; Ballatore, Valentina; Cascinu, Stefano; Tonini, Giuseppe; Carteni, Giacomo; Russo, Antonio; Santini, Daniele.

In: PLoS One, Vol. 10, No. 4, e0120427, 17.04.2015.

Research output: Contribution to journalArticle

Pantano, F, Santoni, M, Procopio, G, Rizzo, M, Iacovelli, R, Porta, C, Conti, A, Lugini, A, Milella, M, Galli, L, Ortega, C, Guida, FM, Silletta, M, Schinzari, G, Verzoni, E, Modica, D, Crucitti, P, Rauco, A, Felici, A, Ballatore, V, Cascinu, S, Tonini, G, Carteni, G, Russo, A & Santini, D 2015, 'The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?', PLoS One, vol. 10, no. 4, e0120427. https://doi.org/10.1371/journal.pone.0120427
Pantano, Francesco ; Santoni, Matteo ; Procopio, Giuseppe ; Rizzo, Mimma ; Iacovelli, Roberto ; Porta, Camillo ; Conti, Alessandro ; Lugini, Antonio ; Milella, Michele ; Galli, Luca ; Ortega, Cinzia ; Guida, Francesco Maria ; Silletta, Marianna ; Schinzari, Giovanni ; Verzoni, Elena ; Modica, Daniela ; Crucitti, Pierfilippo ; Rauco, Annamaria ; Felici, Alessandra ; Ballatore, Valentina ; Cascinu, Stefano ; Tonini, Giuseppe ; Carteni, Giacomo ; Russo, Antonio ; Santini, Daniele. / The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus : A new pharmacodynamic marker?. In: PLoS One. 2015 ; Vol. 10, No. 4.
@article{50127dce38eb431aa11b16bb1f8e561f,
title = "The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?",
abstract = "Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC.",
author = "Francesco Pantano and Matteo Santoni and Giuseppe Procopio and Mimma Rizzo and Roberto Iacovelli and Camillo Porta and Alessandro Conti and Antonio Lugini and Michele Milella and Luca Galli and Cinzia Ortega and Guida, {Francesco Maria} and Marianna Silletta and Giovanni Schinzari and Elena Verzoni and Daniela Modica and Pierfilippo Crucitti and Annamaria Rauco and Alessandra Felici and Valentina Ballatore and Stefano Cascinu and Giuseppe Tonini and Giacomo Carteni and Antonio Russo and Daniele Santini",
year = "2015",
month = "4",
day = "17",
doi = "10.1371/journal.pone.0120427",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus

T2 - A new pharmacodynamic marker?

AU - Pantano, Francesco

AU - Santoni, Matteo

AU - Procopio, Giuseppe

AU - Rizzo, Mimma

AU - Iacovelli, Roberto

AU - Porta, Camillo

AU - Conti, Alessandro

AU - Lugini, Antonio

AU - Milella, Michele

AU - Galli, Luca

AU - Ortega, Cinzia

AU - Guida, Francesco Maria

AU - Silletta, Marianna

AU - Schinzari, Giovanni

AU - Verzoni, Elena

AU - Modica, Daniela

AU - Crucitti, Pierfilippo

AU - Rauco, Annamaria

AU - Felici, Alessandra

AU - Ballatore, Valentina

AU - Cascinu, Stefano

AU - Tonini, Giuseppe

AU - Carteni, Giacomo

AU - Russo, Antonio

AU - Santini, Daniele

PY - 2015/4/17

Y1 - 2015/4/17

N2 - Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC.

AB - Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T and C +T raises were significantly associated with baseline BMI (p=0.0412, 0.0283 and 0.0001). Median TTP was significantly longer in patients with T raise compared to patients without T (10 vs 6, p =0.030), C (8 vs 5, p =0.042) and C+T raise (10.9 vs 5.0, p=0.003). At the multivariate analysis, only C+T increase was associated with improved TTP (p=0.005). T raise (21.0 vs 14.0, p=0.002) and C+T increase (21.0 vs 14.0, p=0.006) were correlated with improved OS but were not significant at multivariate analysis. Conclusion: C+T raise is an early predictor for everolimus efficacy for patients with mRCC.

UR - http://www.scopus.com/inward/record.url?scp=84929493881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929493881&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0120427

DO - 10.1371/journal.pone.0120427

M3 - Article

AN - SCOPUS:84929493881

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0120427

ER -